Metabolic engineering for microbial production of terpenoid products

Inventors

KUMARAN, Ajikumar Parayil • LIM, Chin-Giaw • GHOSH, SOUVIK • Pirie, Christopher • Donald, Jason • Love, Aaron • NAN, Hong • TSENG, Hsien-Chung • Santos, Christine Nicole S. • PHILIPPE, Ryan

Assignees

Manus Bio Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10662442-B2

Patent

Publication Date

2020-05-26

Expiration Date


Abstract

In various aspects and embodiments, the invention relates to bacterial strains and methods for making terpene and terpenoid products. The invention provides bacterial strains with improved carbon flux through the MEP pathway, to thereby increase terpene and/or terpenoid product yield by fermentation with carbon sources such as glucose.

Core Innovation

The disclosed invention describes the production of terpenoids in engineered E. coli by increasing carbon flux through the upstream methylerythritol pathway. The strain produces IPP and DMAPP through an upstream MEP pathway and converts them to a terpenoid through a downstream synthesis pathway. Genetic features include inducible or constitutive expression of the isc operon, iscR deleted in whole or in part or inactivated, and ryhB deleted or inactivated, with greater than 1% of carbon entering glycolysis becoming MEP carbon.

The disclosure describes strategies involving MEP pathway enzymes, including IspB and IspG modifications, reporting changes in product titers and MEP-intermediate concentrations. Specific pathway-gene expression combinations demonstrate increased product A equivalents, reaching approximately 8 to 9-fold under certain conditions. Because the background section is omitted in the source content, the specific problem being solved is not explicitly described in patent.

Claims Coverage

The provided claims identify one independent claim directed to a method for producing a terpenoid using an engineered E. coli strain, encompassing one inventive feature.

Terpenoid production by engineered E. coli

Providing an E. coli strain that produces IPP and DMAPP through an upstream MEP pathway and converts them to a terpenoid through a downstream synthesis pathway, wherein the strain comprises inducible or constitutive expression of the isc operon, deletion or inactivation of iscR in whole or in part, and deletion or inactivation of ryhB, with greater than 1% of carbon entering glycolysis becoming MEP carbon.

The independent claim combines the specified isc operon expression and iscR and ryhB modifications in an E. coli terpenoid-production method with a requirement that more than 1% of glycolysis-entering carbon becomes MEP carbon.

Stated Advantages

The figure summary reports product A improvements generally around 1.1 to 1.7-fold in variant screening results and ispG comparisons, with ispG_G11 increasing products A and B relative to the parent.

Certain pathway-gene expression combinations produce larger reported increases in product A equivalents, reaching approximately 8 to 9-fold under some conditions.

The source content reports increased product titers following Fe-S pathway modifications, including up to 1.5-fold gains with IspG variants and up to 1.5-fold gains with ispB RBS variants.

Documented Applications

Production of a terpenoid using an engineered E. coli strain that produces IPP and DMAPP through the MEP pathway and converts them to a terpenoid through a downstream synthesis pathway.

Fermentation-derived terpenoids for flavors, fragrances, sweeteners, and other consumer or industrial products.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.